Optimizing the management of community-acquired respiratory tract infections in the age of antimicrobial resistance
Author:
- 1 October 2006
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Anti-infective Therapy
- Vol. 4 (5) , 821-835
Abstract
Community-acquired respiratory tract infections (CARTIs) are the most common reason for prescribing antibiotics in the primary care setting. However, over the last decade, the management of CARTIs has become increasingly complicated by the steady increase in prevalence of drug-resistant pathogens responsible for these infections. As a result, significant attention has been directed at understanding the mechanisms of pathogen acquisition of resistance, drivers of resistance and methods for preventing the development of resistance. Data from recent surveillance studies suggest a slowing or decline in resistance rates to agents, such as beta-lactams, macrolides, tetracyclines and folic acid metabolism inhibitors. However, resistance to one antimicrobial family--the fluoroquinolones--while still low, appears to be on the increase. This is of significant concern given the rapid increase in resistance noted with older antibiotics in recent history. While the clinical implications of antibacterial resistance are poorly understood, the overall rates of antimicrobial resistance, as reported in recent surveillance studies, do not correspond to current rates of failure in patients with CARTIs. This disconnection between laboratory-determined resistance and clinical outcome has been termed the in vitro-in vivo paradox and several explanations have been offered to explain this phenomenon. Solving the problem of antimicrobial resistance will be multifactorial. Important factors in this effort include the education of healthcare providers, patients and the general healthcare community regarding the hazards of inappropriate antibiotic use, prevention of infections through vaccination, development of accurate, inexpensive and timely point-of-care diagnostic tests to aid in patient assessment, institution of objective treatment guidelines and use of more potent agents, especially those with a focused spectrum of activity, earlier in the treatment of CARTIs as opposed to reserving them as second-line treatment options. Ultimately, the single-most important factor will be the judicious use of antibiotics, as fewer antibiotic prescriptions lead to fewer antimicrobial-resistant bacteria.Keywords
This publication has 107 references indexed in Scilit:
- Macrolide use identified as risk factor for macrolide-resistant Streptococcus pneumoniae in a 17-center case-control studyEuropean Journal of Clinical Microbiology & Infectious Diseases, 2006
- Impact of Pneumococcal Polysaccharide Vaccine (Prevnar) on Middle Ear Fluid in Children Undergoing Tympanostomy Tube InsertionThe Laryngoscope, 2004
- Randomized, Placebo‐Controlled Clinical Trial of Oral Azithromycin Prophylaxis against Respiratory Infections in a High‐Risk, Young Adult PopulationClinical Infectious Diseases, 2001
- Excessive Antibiotic Use for Acute Respiratory Infections in the United StatesClinical Infectious Diseases, 2001
- Identification of Two Penicillin-Binding Multienzyme Complexes in Haemophilus influenzaeBiochemical and Biophysical Research Communications, 1999
- Clarithromycin in vitro activity enhanced by its major metabolite, 14-hydroxyclarithromycinDiagnostic Microbiology and Infectious Disease, 1992
- Risk Factors and Response to Antibiotic Therapy in Adults with Bacteremic Pneumonia Caused by Penicillin-Resistant PneumococciNew England Journal of Medicine, 1987
- Antibacterial Activity of Desacetylcefotaxime Alone and in Combination with CefotaximeClinical Infectious Diseases, 1982
- AMPICILLIN-RESISTANT HÆMOPHILUS INFLUENZÆ TYPE B POSSESSING A TEM-TYPE β-LACTAMASE BUT LITTLE PERMEABILITY BARRIER TO AMPICILLINThe Lancet, 1975
- Substrate‐and Antibiotic‐Binding Sites at the Peptidyl‐Transferase Centre of Escherichia coli RibosomesEuropean Journal of Biochemistry, 1971